USE OF A CD40:CD154 BINDING INTERRUPTOR TO PREVENT COUNTER ADAPTIVE IMMUNE RESPONSES, PARTICULARLY GRAFT REJECTION - Patent 0980259

(19)

(11)

EP 0 980 259 A1

(12)

(43)	Date of publication:
	23.02.2000 Bulletin 2000/08

(21)	Application number: 98922381.3

(22)	Date of filing: 15.05.1998

(51)	International Patent Classification (IPC)⁷: A61K 39/395, A61K 38/17, A61K 31/57, A61K 31/445, A61K 38/13 // (A61K39/395, 38:13),(A61K39/395, 31:57),(A61K39/395, 31:445)

(86)	International application number:
	PCT/US9810/075

(87)	International publication number:
	WO 9852/606 (26.11.1998 Gazette 1998/47)

(84)	Designated Contracting States:
	AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
	Designated Extension States:
	AL LT LV MK RO SI

(30)

Priority:

17.05.1997 US 46791 P
11.06.1997 US 49389 P
12.05.1998 US 85145

(71)	Applicants:
	BIOGEN, INC. CambridgeMassachusetts 02142 (US) THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE NAVY Arlington, VA 22217-5660 (US)

(72)	Inventors:
	KIRK, Allan, D. Potomac, MD 20854 (US) HARLAN, David, M. Bethesda, MD (US) THOMAS, David Houston, TX (US) KAUFFMAN, Michael Jamaica Plain, MA 02139-4618 (US) BURKLY, Linda West Newton, MA 02165 (US)

(74)	Representative: UEXKÜLL & STOLBERG
	PatentanwälteBeselerstrasse 4 22607 Hamburg 22607 Hamburg (DE)

(54)	USE OF A CD40:CD154 BINDING INTERRUPTOR TO PREVENT COUNTER ADAPTIVE IMMUNE RESPONSES, PARTICULARLY GRAFT REJECTION